Brief: Intellia Therapeutics Announces Initiation Of Haelo Phase 3 Study Of Ntla-2002
07/10/2024 12:42
Oct 7 (Reuters) - Intellia Therapeutics Inc NTLA.O :
* INTELLIA THERAPEUTICS ANNOUNCES INITIATION OF HAELO PHASE
3
STUDY OF NTLA-2002, AN INVESTIGATIONAL IN VIVO CRISPR GENE
EDITING TREATMENT FOR HEREDITARY ANGIOEDEMA (HAE)
Source text for Eikon: ID:nGNX1n2fxJ
Further company coverage: NTLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)